A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older with Cystic Fibrosis

Project: Research project

Description

A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older with Cystic Fibrosis
StatusActive
Effective start/end date3/21/191/1/21

Funding

  • Vertex Pharmaceuticals Incorporated

Fingerprint

Double-Blind Method
Cystic Fibrosis
Safety
VX